Lin Ping-I, Khin Kyi Shinn, John James R, Walker Adam K, Chen Yi-Chia, Nayeem Nawar, Messias Erick
Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW 2033, Australia.
Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO 63103, USA.
Children (Basel). 2024 Dec 23;11(12):1558. doi: 10.3390/children11121558.
: In utero exposure to painkillers has raised concerns regarding its potential impact on neurodevelopmental disorders, such as autism spectrum disorder (ASD). This study investigates the association between in utero exposure to painkillers and trajectories of hyperactivity and emotional problems in children with and without ASD, separately. Data were drawn from 5107 participants enrolled in the Longitudinal Study of Australian Children. Emotional and behavioral problems were assessed using the Strengths and Difficulties Questionnaire at ages 4, 6, and 8 years. ASD diagnosis was determined based on parental self-report by age 12. To examine the association between the exposure and the outcomes, mixed linear models were applied to assess the impact of in utero exposure to painkillers on hyperactivity and emotional problems, controlling for sex, time, and other perinatal risk factors. The interaction term between exposure and time was included to evaluate the effect of exposure on the trajectory over time. : In utero exposure to painkillers did not significantly affect hyperactivity or emotional problem trajectories in children with ASD. However, in non-ASD children, painkiller exposure was associated with worsening emotional problems by age 8, with males being affected to a greater extent than females. Further, emotional problem scores increased over time by gender, reflecting developmental challenges in early childhood. : These findings indicate that prenatal painkiller exposure is unlikely to be a major determinant of the severity of neurodevelopmental outcomes in autistic children, but its role in neurodevelopmental outcomes among neurotypical children warrants further investigation. Future research should prioritize precise exposure assessments and integrate multi-environment interactions to further elucidate the long-term impacts of prenatal painkiller use.
子宫内接触止痛药引发了人们对其可能影响神经发育障碍(如自闭症谱系障碍,ASD)的担忧。本研究分别调查了子宫内接触止痛药与患有和未患有ASD的儿童多动和情绪问题轨迹之间的关联。数据来自参与澳大利亚儿童纵向研究的5107名参与者。在4岁、6岁和8岁时使用优势与困难问卷评估情绪和行为问题。ASD诊断根据12岁时父母的自我报告确定。为了检验暴露与结果之间的关联,应用混合线性模型评估子宫内接触止痛药对多动和情绪问题的影响,同时控制性别、时间和其他围产期风险因素。纳入暴露与时间之间的交互项以评估暴露对随时间变化轨迹的影响。
子宫内接触止痛药对患有ASD的儿童的多动或情绪问题轨迹没有显著影响。然而,在非ASD儿童中,接触止痛药与8岁时情绪问题恶化有关,男性受影响的程度大于女性。此外,情绪问题得分随性别随时间增加,反映了幼儿期的发育挑战。
这些发现表明,产前接触止痛药不太可能是自闭症儿童神经发育结果严重程度的主要决定因素,但其在神经典型儿童神经发育结果中的作用值得进一步研究。未来的研究应优先进行精确的暴露评估,并整合多环境相互作用,以进一步阐明产前使用止痛药的长期影响。